Nature Communications (Jun 2022)
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
- Hiam Chemaitelly,
- Houssein H. Ayoub,
- Sawsan AlMukdad,
- Peter Coyle,
- Patrick Tang,
- Hadi M. Yassine,
- Hebah A. Al-Khatib,
- Maria K. Smatti,
- Mohammad R. Hasan,
- Zaina Al-Kanaani,
- Einas Al-Kuwari,
- Andrew Jeremijenko,
- Anvar Hassan Kaleeckal,
- Ali Nizar Latif,
- Riyazuddin Mohammad Shaik,
- Hanan F. Abdul-Rahim,
- Gheyath K. Nasrallah,
- Mohamed Ghaith Al-Kuwari,
- Adeel A. Butt,
- Hamad Eid Al-Romaihi,
- Mohamed H. Al-Thani,
- Abdullatif Al-Khal,
- Roberto Bertollini,
- Laith J. Abu-Raddad
Affiliations
- Hiam Chemaitelly
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University
- Houssein H. Ayoub
- Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University
- Sawsan AlMukdad
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University
- Peter Coyle
- Hamad Medical Corporation
- Patrick Tang
- Department of Pathology, Sidra Medicine
- Hadi M. Yassine
- Biomedical Research Center, Member of QU Health, Qatar University
- Hebah A. Al-Khatib
- Biomedical Research Center, Member of QU Health, Qatar University
- Maria K. Smatti
- Biomedical Research Center, Member of QU Health, Qatar University
- Mohammad R. Hasan
- Department of Pathology, Sidra Medicine
- Zaina Al-Kanaani
- Hamad Medical Corporation
- Einas Al-Kuwari
- Hamad Medical Corporation
- Andrew Jeremijenko
- Hamad Medical Corporation
- Anvar Hassan Kaleeckal
- Hamad Medical Corporation
- Ali Nizar Latif
- Hamad Medical Corporation
- Riyazuddin Mohammad Shaik
- Hamad Medical Corporation
- Hanan F. Abdul-Rahim
- Department of Public Health, College of Health Sciences, QU Health, Qatar University
- Gheyath K. Nasrallah
- Biomedical Research Center, Member of QU Health, Qatar University
- Mohamed Ghaith Al-Kuwari
- Primary Health Care Corporation
- Adeel A. Butt
- Department of Population Health Sciences, Weill Cornell Medicine, Cornell University
- Hamad Eid Al-Romaihi
- Ministry of Public Health
- Mohamed H. Al-Thani
- Ministry of Public Health
- Abdullatif Al-Khal
- Hamad Medical Corporation
- Roberto Bertollini
- Ministry of Public Health
- Laith J. Abu-Raddad
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University
- DOI
- https://doi.org/10.1038/s41467-022-30895-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
The SARS-CoV-2 Omicron variant has subvariants with divergent properties but relative vaccine effectiveness has not been characterized. Here, the authors show that mRNA vaccine effectiveness is similar for the subvariants BA.1 and BA.2, with a decline three months after the second dose and increase after the booster.
